Study #2019-0142
A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-
MD Anderson Study Status
Not Accepting
Treatment Agent
Pembrolizumab, Gemcitabine, Cisplatin, Placebo
Description
A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eligible patients.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Bladder Cancer
Study phase:
Phase III
Physician name:
Arlene Siefker-Radtke
Department:
Genitourinary Medical Oncology
For general questions about clinical trials:
1-855-982-0789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.